Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OPT NASDAQ:ORKA NASDAQ:RAPP NASDAQ:TARA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOPTOpthea$3.41$3.41$1.79▼$6.30$524.83M1.17N/AN/AORKAOruka Therapeutics$13.60+0.1%$12.82$5.49▼$52.32$508.82M-0.35159,251 shs142,850 shsRAPPRapport Therapeutics$14.15-1.5%$12.70$6.43▼$29.74$524.11M0.6161,022 shs124,280 shsTARAProtara Therapeutics$3.06-1.3%$3.12$1.60▼$10.48$119.60M1.42203,681 shs301,824 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOPTOpthea0.00%0.00%0.00%0.00%+50.22%ORKAOruka Therapeutics+0.07%-4.56%+7.85%+26.98%+1,359,999,900.00%RAPPRapport Therapeutics-1.46%-11.84%+19.92%+24.89%-37.72%TARAProtara Therapeutics-1.29%-8.11%+10.07%-14.53%+37.22%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOPTOpthea0.3895 of 5 stars1.10.00.00.02.00.80.6ORKAOruka Therapeutics2.2738 of 5 stars3.60.00.00.01.12.50.6RAPPRapport Therapeutics1.2157 of 5 stars3.50.00.00.00.60.80.6TARAProtara Therapeutics1.8255 of 5 stars3.61.00.00.02.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOPTOpthea 2.17Hold$1.33-60.90% DownsideORKAOruka Therapeutics 3.20Buy$40.38196.88% UpsideRAPPRapport Therapeutics 3.00Buy$28.0097.88% UpsideTARAProtara Therapeutics 3.14Buy$20.50569.93% UpsideCurrent Analyst Ratings BreakdownLatest TARA, RAPP, OPT, and ORKA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2025ORKAOruka TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.007/21/2025ORKAOruka TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.007/8/2025RAPPRapport TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$28.005/22/2025ORKAOruka TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/22/2025ORKAOruka TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$44.005/22/2025TARAProtara TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$21.005/15/2025ORKAOruka TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOPTOpthea$120K4,373.61N/AN/A($0.56) per share-6.09ORKAOruka TherapeuticsN/AN/AN/AN/A$10.84 per shareN/ARAPPRapport TherapeuticsN/AN/AN/AN/A$8.35 per shareN/ATARAProtara TherapeuticsN/AN/AN/AN/A$4.77 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOPTOpthea-$220.24MN/A0.00N/AN/AN/AN/AN/A8/29/2025 (Estimated)ORKAOruka Therapeutics-$83.72M-$4.51N/AN/AN/AN/A-25.66%-23.39%8/7/2025 (Estimated)RAPPRapport Therapeutics-$78.31M-$3.45N/AN/AN/AN/A-25.48%-24.63%8/14/2025 (Estimated)TARAProtara Therapeutics-$44.60M-$1.72N/AN/AN/AN/A-36.37%-33.29%8/5/2025 (Estimated)Latest TARA, RAPP, OPT, and ORKA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025RAPPRapport Therapeutics-$0.87N/AN/AN/AN/AN/A8/7/2025Q1 2025ORKAOruka Therapeutics-$0.48N/AN/AN/AN/AN/A8/5/2025Q2 2025TARAProtara Therapeutics-$0.43N/AN/AN/AN/AN/A5/14/2025Q1 2025ORKAOruka Therapeutics-$0.57-$0.40+$0.17-$0.40N/AN/A5/8/2025Q1 2025RAPPRapport Therapeutics-$0.77-$0.68+$0.09-$0.68N/AN/A5/8/2025Q1 2025TARAProtara Therapeutics-$0.47-$0.29+$0.18-$0.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOPTOptheaN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ATARAProtara TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOPTOptheaN/A1.57N/AORKAOruka TherapeuticsN/A30.0330.03RAPPRapport TherapeuticsN/A31.0131.01TARAProtara TherapeuticsN/A18.0318.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOPTOpthea55.95%ORKAOruka Therapeutics56.44%RAPPRapport TherapeuticsN/ATARAProtara Therapeutics38.13%Insider OwnershipCompanyInsider OwnershipOPTOpthea3.20%ORKAOruka Therapeutics24.69%RAPPRapport TherapeuticsN/ATARAProtara Therapeutics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOPTOpthea8153.91 million148.99 millionNot OptionableORKAOruka TherapeuticsN/A37.44 million28.20 millionN/ARAPPRapport TherapeuticsN/A36.50 millionN/AN/ATARAProtara Therapeutics3038.58 million35.34 millionOptionableTARA, RAPP, OPT, and ORKA HeadlinesRecent News About These CompaniesProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1 at 5:52 PM | gurufocus.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1 at 4:08 PM | globenewswire.comProtara Therapeutics (TARA) to Release Quarterly Earnings on TuesdayJuly 30 at 8:25 AM | marketbeat.comAnalysts Set Protara Therapeutics, Inc. (NASDAQ:TARA) PT at $20.50July 30 at 3:09 AM | americanbankingnews.comProtara Therapeutics, Inc. (NASDAQ:TARA) Receives Consensus Recommendation of "Buy" from BrokeragesJuly 25, 2025 | marketbeat.comProtara Therapeutics (NASDAQ:TARA) Shares Up 11% - Still a Buy?July 22, 2025 | marketbeat.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - The Manila TimesJuly 2, 2025 | manilatimes.netMProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - MorningstarJuly 2, 2025 | morningstar.comMProtara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial Community - NasdaqJuly 2, 2025 | nasdaq.comProtara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 1, 2025 | globenewswire.comProtara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial CommunityJune 30, 2025 | quiverquant.comQProtara Therapeutics Announces Addition to the Russell 3000® IndexJune 30, 2025 | globenewswire.comProtara Therapeutics, Inc. (TARA) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comRAPT Therapeutics Appoints Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D. to Board of DirectorsJune 23, 2025 | quiverquant.comQProtara Therapeutics: Marching On To A Hopefully Eventful Back Half Of 2025June 14, 2025 | seekingalpha.comChutes & Ladders—Protara gears up for next steps with commercial proJune 7, 2025 | fiercebiotech.comFThe Escalator: Digitas Health, Bristol Myers Squibb, Inizio Evoke and moreJune 4, 2025 | mmm-online.comMProtara Therapeutics names new Chief Commercial OfficerJune 4, 2025 | investing.comProtara Therapeutics Announces Appointment of William Conkling as Chief Commercial OfficerJune 2, 2025 | globenewswire.comJones Trading Initiates Coverage of Protara Therapeutics (TARA) with Buy RecommendationMay 23, 2025 | msn.comRichard Levy Spends US$64k On Protara Therapeutics StockMay 22, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesRocket Lab: A Parabolic Run Meets a Healthy PullbackBy Ryan Hasson | July 23, 2025View Rocket Lab: A Parabolic Run Meets a Healthy PullbackPelosi Makes Big Bet on Broadcom—Here’s Why It MattersBy Gabriel Osorio-Mazilli | July 15, 2025View Pelosi Makes Big Bet on Broadcom—Here’s Why It MattersPalantir Gets Price Hike From Wedbush Amid High ValuationBy Chris Markoch | July 15, 2025View Palantir Gets Price Hike From Wedbush Amid High ValuationCSX Stock Rally: Strong Options Flow, Analyst Price TargetsBy Jeffrey Neal Johnson | July 18, 2025View CSX Stock Rally: Strong Options Flow, Analyst Price TargetsPalantir Bulls and Bears Set for an August Showdown By Chris Markoch | July 22, 2025View Palantir Bulls and Bears Set for an August Showdown TARA, RAPP, OPT, and ORKA Company DescriptionsOpthea NASDAQ:OPT$3.41 0.00 (0.00%) As of 08/1/2025Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Oruka Therapeutics NASDAQ:ORKA$13.60 +0.01 (+0.07%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$13.60 0.00 (0.00%) As of 08/1/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.Rapport Therapeutics NASDAQ:RAPP$14.15 -0.21 (-1.46%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$14.16 +0.01 (+0.07%) As of 08/1/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.Protara Therapeutics NASDAQ:TARA$3.06 -0.04 (-1.29%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.15 +0.09 (+2.91%) As of 08/1/2025 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
